Tyra Biosciences Resignation of Director and Interim Clinical Results Announcement

On October 24, 2024, Tyra Biosciences, Inc. (NASDAQ: TYRA) announced the resignation of Siddarth Subramony, Ph.D., from the Board of Directors and the Compensation Committee, with the resignation being effective immediately. Dr. Subramony’s departure was confirmed to not be linked to any disagreement with the company’s operations, policies, or practices.

Furthermore, on October 25, 2024, Tyra Biosciences disclosed plans to conduct a conference call and webcast, scheduled to begin at 8:00 a.m. Eastern Time. The purpose of the event is to share interim clinical results from the SURF301 Phase 1/2 study of TYRA-300 in metastatic urothelial cancer (mUC). The webcast will be accessible via the company’s corporate website under the “For Investors” page.

Tyra Biosciences also revealed interim clinical proof-of-concept data for TYRA-300 in patients with mUC from the ongoing SURF301 study. As of the August 15, 2024, data cutoff date, preliminary findings indicated encouraging responses to TYRA-300, with anti-tumor activity observed in patients receiving doses of 90 mg QD or higher. The safety profile of TYRA-300 appeared favorable, with manageable toxicities noted across various dose levels.

Moreover, Tyra Biosciences cautioned that forward-looking statements in the report should be interpreted with care, as they may not align with actual outcomes due to inherent risks and uncertainties in the business, including evolving clinical trial data, uncertainties in product development, and regulatory challenges.

The Company provided Exhibit 99.1, a slide presentation, along with the filing, detailing the interim clinical results. Tyra emphasized the importance of not placing undue reliance on forward-looking statements, as they are subject to change based on subsequent events or circumstances.

No significant financial details were disclosed in the report filed with the Securities and Exchange Commission (SEC) on Form 8-K.

This article does not constitute any investment advice. Interested parties are encouraged to review the complete filing on the SEC’s website or Tyra Biosciences’ investor relations page for full details on the matter.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Tyra Biosciences’s 8K filing here.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.